Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study

• Published in: BMC psychiatry Vol. 20; no. 1; pp. 485 - 12
• Main Authors: Iwanami, Akira, Saito, Kazuhiko, Fujiwara, Masakazu, Okutsu, Daiki, Ichikawa, Hironobu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.10.2020; BioMed Central; BMC
• Subjects: Adrenergic alpha-2 Receptor Agonists - therapeutic use; Adult; Adults; Attention deficit disorder with hyperactivity; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention deficit hyperactivity disorder; Blood pressure; Bradycardia; Central Nervous System Stimulants - therapeutic use; Clinical trials; Complications and side effects; Constipation; Delayed-Action Preparations - therapeutic use; Dose-Response Relationship, Drug; Double-Blind Method; Drug dosages; Drug use; Executive function; Guanfacine; Guanfacine - adverse effects; Humans; Hyperactivity; Japan; Labels; Medical research; Mental disorders; Patients; Psychiatric Status Rating Scales; Psychiatry; Quality of Life; Rhinopharyngitis; Safety; Thirst; Treatment Outcome; Japan; Attention deficit disorder with hyperactivity; Treatment outcome; Adult; Guanfacine; Safety

To assess the safety and efficacy of long-term administration of guanfacine extended-release (GXR) in adults with attention-deficit/hyperactivity disorder (ADHD). In this open-label, long-term, phase 3 extension study in Japan, 150 patients transitioned from a double-blind trial, and 41 newly enroll...